Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 898-901, February 1, 2007. doi: 10.1158/1078-0432.CCR-06-1008
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hefler, L. A.
Right arrow Articles by Zeillinger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hefler, L. A.
Right arrow Articles by Zeillinger, R.

Imaging, Diagnosis, Prognosis

Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

Lukas A. Hefler1, Alexander Mustea4, Dominique Könsgen4, Nicole Concin5, Berno Tanner6, Reiner Strick7, Georg Heinze2, Christoph Grimm1, Eva Schuster1, Clemens Tempfer1, Alexander Reinthaller1 and Robert Zeillinger1,3

Authors' Affiliations: 1 Department of Obstetrics and Gynecology and 2 Core Unit for Medical Statistics and Informatics, Medical University of Vienna; 3 Ludwig Boltzmann Institute for Gynecology and Gynecological Oncology, Vienna, Austria; 4 Department of Obstetrics and Gynecology, Charité/Campus Virchow-Klinikum, University Medicine of Berlin, Germany; 5 Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria; 6 Department of Obstetrics and Gynecology, Johannes Gutenberg-University, Mainz, Germany; and 7 Department of Obstetrics and Gynecology, Friedrich-Alexander-University Erlangen-Nuernberg, Erlangen, Germany

Requests for reprints: Lukas Hefler, Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-2962; Fax: 43-1-40400-2911; E-mail: lukas.hefler{at}meduniwien.ac.at.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis and vascular permeability, is involved in various steps of ovarian carcinogenesis. Gene polymorphisms within the gene encoding VEGF were shown to be independently associated with an adverse outcome in various malignancies. No data are available for ovarian cancer.

Experimental Design: In the present multicenter study, we examined three common polymorphisms within the VEGF gene (–634G/C, –1154G/A, and –2578C/A) known to be associated with an increased VEGF production in 563 Caucasian patients with ovarian cancer from Austria and Germany using pyrosequencing. Results were correlated with clinical data.

Results: The three investigated polymorphisms did not correlate with any of the investigated clinicopathologic variables. In univariate and multivariate models, no significant correlations between any polymorphism and patients' overall survival were ascertained. Simultaneous carriage of the three homozygous genotypes (i.e., VEGF –634C/C, VEGF –1154G/G, VEGF –2578C/C) known to be associated with increased VEGF expression in an individual patient, however, was independently associated with a shortened overall survival (hazard ratio, 2.1; 95% confidence interval, 1.1-3.9; P = 0.02).

Conclusions: We present the first data on VEGF gene polymorphisms in ovarian cancer. Simultaneous carriage of the three investigated homozygous genotypes was shown to be an independent adverse prognosticator of overall survival.

Angiogenesis has been established as a crucial factor in carcinogenesis influencing tumor growth, invasion, and the formation of metastases (1, 2). Growth stress such as hypoxia induces connective tissue or tumor cells to secrete angiogenic molecules, thereby influencing the balance between proangiogenic and antiangiogenic factors (2, 3).

Vascular endothelial growth factor (VEGF), a dimeric glycoprotein with four splice variants consisting of 121, 165, 189, and 206 amino acid residues, is a proangiogenic molecule that elicits its effects by acting as an endothelial cell mitogen and a mediator of increased vascular permeability via binding to its receptors VEGF receptor I and kinase domain receptor (4).

In ovarian cancer, in vitro studies showed that VEGF is crucially involved in various steps of ovarian carcinogenesis (5–7). VEGF was shown to be associated with the promotion of angiogenesis in early stage ovarian cancer, suggesting that VEGF-driven angiogenesis might be an early event in ovarian carcinogenesis (8). Recently, immunohistochemically detected VEGF overexpression and elevated serum levels of VEGF were shown to be associated with an impaired prognosis (9, 10).

The VEGF gene is located on chromosome 6p21.3. At least 30 single-nucleotide polymorphisms in this gene have been described in the literature. Among these, the VEGF –634G/C, –1154G/A, and –2578C/A polymorphisms have been shown to be associated with an increased VEGF production (11–13). Recently, VEGF polymorphisms were evaluated in melanoma (14) and bladder (15), lung (16), prostate (17), and breast cancer (18, 19) patients. Various studies focused on the prognostic potential of VEGF polymorphisms (15, 18, 19). To the authors' knowledge, no data are available on VEGF polymorphisms in ovarian cancer.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Patients. A total of 563 patients with ovarian cancer were included in the present study (Medical University of Vienna, Austria: n = 176; Charité, Campus Virchow-Klinikum, Berlin, Germany: n = 157; Medical University of Innsbruck, Austria: n = 75; Friedrich-Alexander-University Erlangen-Nuernberg, Germany: n = 84; Johannes Gutenberg-University, Mainz, Germany: n = 71). The respective Institutional Review Boards approved the present study. Patients were treated between November 1988 and August 2004 and followed up according to established protocols of the respective institutions. Patients were treated according to standards of the respective institution with hysterectomy, bilateral salpingo-oophorectomy, pelvic and/or paraaortic lymphadenectomy, appendectomy, and omentectomy. All patients with tumor stages Ic to III and all patients with clear cell carcinoma received six cycles of adjuvant platinum-based chemotherapy. Patients' characteristics are shown in Table 1 .


View this table:
[in this window]
[in a new window]

  		Table 1. Patients' characteristics

 
DNA extraction. DNA was isolated from centrifuged blood clots (Vienna, Innsbruck) by a modified DNAzol procedure (20), from EDTA-blood (Berlin, Erlangen, Vienna) using the QIAamp DNA Blood Midi Kit (Qiagen, Inc., Hilden, Germany), or from formalin-fixed paraffin-embedded tissue (Mainz; ref. 21). The extracted DNA was stored at 4°C until analyzed.

PCR. The primers VEGF–634 SE 5'-GGAAGAGAGAGACGGGGTCA-3', VEGF–634 AS 5'-GGTCACCCCCAAAAGCAG-3', VEGF–1154 SE 5'-CTTGGTGGGGGTCGAGCT-3', VEGF–1154 AS 5'-GGACAGGCGAGCCTCAGC-3', VEGF–2578 SE 5'-AGAGGCTATGCCAGCTGTAGG-3', and VEGF–2578 AS 5'-AACAAAGTTGGGGCTCTGAG-3' were used to amplify fragments of the VEGF gene. Antisense primers were biotinylated. PCR was carried out in a total volume of 25 µL including 25 ng template, 5 pmol of each sense and antisense primers and puReTaq Ready-To-Go PCR Beads (Amersham Biosciences, Little Chalfont, United Kingdom), which contain 2.5 units of puReTaq DNA polymerase, 10 mmol/L Tris-HCl (pH 9.0 at room temperature), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 200 µmol/L dATP, dCTP, dGTP, and dTTP, and stabilizers, including bovine serum albumin. PCR was done on a Perkin-Elmer GeneAmp PCR system 9600 with 40 cycles at 94°C for 30 s, at 58°C (VEGF–2578, VEGF–1154) or 57°C (VEGF–634) for 30 s, and 72°C for 30 s. The reaction was preceded by a primary denaturation step at 94°C for 1 min and incubated at 72°C for 7 min.

Detection of polymorphisms by pyrosequencing. Three common functional single nucleotide polymorphisms (–634 G/C, –1154G/A, –2578C/A) within the VEGF gene were detected using Pyrosequencer PSQ 96 and the PSQ 96 SNP Reagent Kit (Pyrosequencing AB, Uppsala, Sweden). Twenty-five microliters of PCR product were used for pyrosequencing according to the instruction of the manufacturer. Five picomoles of the sequencing primers VEGF–634 SEQ 5'-GTGCGAGCAGCGAAA-3', VEGF–1154 SEQ 5'-CGAGCCGCGTGTGGA-3', and VEGF–2578 SEQ 5'-AGGCCAGACCCTGGCA-3' were applied to detect the polymorphisms.

Statistics. After testing for normality using Kolmogorov-Smirnov test, the following values were found to be normally distributed (i.e., P > 0.05) and therefore were given as means (SD): age of patients, time to recurrent disease, and time of follow-up. {chi}2 tests were used to compare frequencies of VEGF genotypes between groups defined by clinicopathologic variables. Presence of all three of the homozygous genotypes (i.e., VEGF –634C/C, VEGF –1154G/G, VEGF –2578C/C) in an individual was shown to be associated with an increased VEGF production (11–13). Therefore, further statistical analysis focused at comparing the end point of overall survival of the group of patients with simultaneous carriage of these three genotypes (n = 29) with all other patients. Survival times of patients with no evidence of disease, with stable disease, and patients having died of non-cancer-related events were censored with the last follow-up date. Survival times of patients who died of disease and of patients with progressive disease at the time of last follow-up were not censored. Survival probabilities were calculated by the product limit method of Kaplan and Meier and resulting survival curves were compared using the Breslow test.

To evaluate the simultaneous carriage of these three genotypes as an independent predictor of survival, a multivariate Cox regression model was estimated comprising the clinically established Fédération Internationale des Gynaecologistes et Obstetristes (FIGO) stage (II-IV versus I), tumor grade (2-3 versus 1), age of patients (>70 versus ≤70 years), and the newly investigated variable simultaneous carriage of these three genotypes as independent variables. Interactions between the simultaneous carriage of these three genotypes and FIGO stage, tumor grade, and age of patient were tested for statistical significance. The proportional hazards assumption of the Cox model was visually checked by plotting Schoenfeld residuals of each variable against time and tested by evaluating the statistical significance of the interaction of each variable with log time.

As our study was designed as a multicenter study to generate as many DNA samples as possible, we did not carry out any power analysis before the study. Therefore, we cannot report on any original study power. However, we did a post hoc study power, as follows. The power to detect a hazard ratio of a given magnitude for a polymorphism depends on the distribution of the genotypes of that polymorphism, on the distribution of survival time, and on the distribution of follow-up time. Using the distributions as they present in our data, we calculated a post hoc power of 80% for detecting a hazard ratio of 1.55 for VEGF –634G/C, 1.95 for VEGF –1154G/A, and 1.7 for VEGF –2578C/A. In comparison, the observed hazard ratios for these polymorphisms were 1.2, 1.25, and 0.92, respectively.

The SAS System (version 9.1, SAS Institute, Inc., Cary, NC) and the SPSS statistical software system (SPSS 11.0, SPSS, Inc., Chicago, IL) were used for statistical computations. We used the SAS/Genetics software (version 9.1, SAS Institute) to test for the presence of any linkage disequilibrium. Two-sided P < 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
The frequencies of the genotypes were 45.1% (GG), 46.8% (GC), and 8.1% (CC) for VEGF –634G/C; 41.4% (GG), 46.1% (GA), and 12.5% (AA) for VEGF –1154G/A; and 25.5% (CC), 50.5% (CA), and 24.0% (AA) for VEGF –2578C/A; all were in Hardy-Weinberg equilibrium (P = 0.08, P = 0.8, and P = 0.9, respectively). All three VEGF polymorphisms were in linkage disequilibrium [VEGF –634G/C and VEGF –1154G/A: Lewontin's D', D' = –0.74 (P < 0.001); VEGF –634G/C and VEGF –2578C/A: D' = –0.83 (P < 0.001); and VEGF –1154G/A and VEGF –2578C/A: D' = 0.79 (P < 0.001)] within the study population. No significant associations between the three investigated VEGF polymorphisms as well as the simultaneous carriage of the three homozygous genotypes and the clinicopathologic variables FIGO stage, tumor grade, and age of patients at diagnosis were ascertained.

In a univariate analysis, FIGO stage, tumor grade, age of patients at diagnosis, and the simultaneous carriage of the three homozygous genotypes, VEGF –634C/C, VEGF –1154G/G, and VEGF –2578C/C (n = 29), were associated with overall survival (Table 2 ; Fig. 1 ). When genotypes were ascertained independently, no significant association was found. In a multivariate Cox regression model, these results remained unchanged (Table 2). No interactions between the simultaneous carriage of the genotypes VEGF –634C/C, VEGF –1154G/G, and VEGF –2578C/C and FIGO state, tumor grade, or age of patient at diagnosis could be statistically verified (P = 0.9, P = 0.9, and P = 0.7, respectively). Thus, the effect of simultaneous carriage of the genotypes found in multiple Cox regression analysis is independent of the level of a patient's FIGO stage, tumor grade, or age at diagnosis. No significant violations of the proportional hazards assumption could be detected for any of the variables entering the multivariate Cox model.


View this table:
[in this window]
[in a new window]

  		Table 2. Univariate Kaplan-Meier analysis and multivariate Cox regression model of prognostic covariates in patients with ovarian cancer

 

Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 1. Kaplan-Meier curves including the 95% confidence bands on overall survival of patients with ovarian cancer. Simultaneous carriage of the three homozygous genotypes, VEGF –634C/C, VEGF –1154G/G, and VEGF –2578C/C (B), was compared with all other combinations of genotypes (A).

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Various studies have investigated gene polymorphisms in patients with ovarian cancer. Relatively few data have been published on their prognostic effect (22, 23). The present multicenter study was set up to evaluate polymorphisms within candidate genes as prognostic markers in a large series of Caucasian patients with ovarian cancer. Based on the important role of VEGF-driven angiogenesis in ovarian carcinogenesis and based on previously published promising data on VEGF polymorphisms in other malignancies (15, 18, 19), we ascertained the prognostic effect of three common functional polymorphisms within the VEGF gene. We aimed at establishing a critical combination of VEGF genotypes as independent prognostic variables.

To our best knowledge, we are the first to report on VEGF polymorphisms in patients with ovarian cancer. In our series, VEGF genotypes were not associated with any investigated clinicopathologic variable. With respect to patients' prognosis, none of the VEGF genotypes alone showed any statistical significance. The VEGF –634C/C, –1154G/G, and –2578C/C genotypes have been shown to be associated with an increased VEGF production (11–13). Therefore, it can be reasonably speculated that simultaneous carriage of these three homozygous genotypes would lead to the highest circulating VEGF value. In our series, these patients had a significantly impaired overall survival. This finding is biologically plausible. Furthermore, we and others have previously shown that patients with elevated serum VEGF levels have a shortened survival (10).

We found a critical combination of VEGF genotypes to be independently associated with survival in a large series of patients with ovarian cancer. These data are new and biologically plausible. The clinical value of these results in the beginning era of bevacizumab (24–28) and other even newer VEGF inhibitors, such as sorafenib (29) and sunitinib (30), remains to be proved.


   Acknowledgments
 
We thank Dan Casire Castillo-Tong for selecting PCR and pyroseqencing primer sequences.


   Footnotes
 
Grant support: Ludwig Boltzmann Foundation, Institute for Gynecology and Gynecologic Oncology.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/24/06; revised 9/ 9/06; accepted 10/ 6/06.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.[CrossRef][Medline]
  2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995;1:27–31.[CrossRef][Medline]
  3. Damert A, Ikeda E, Risau W. Activator protein 1 binding potentiates the hypoxia induced transcriptional activation of vascular endothelial growth factor expression in C6 glioma cells. Biochem J 1997;327:419–23.
  4. Neufeld G, Cohen T, Gitay-Goren H, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996;15:153–8.[CrossRef][Medline]
  5. Borgstrom P, Hillan KJ, Sriramarao P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032–9.[Abstract/Free Full Text]
  6. Mu J, Abe Y, Tsutsui T, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 1996;87:963–71.[CrossRef][Medline]
  7. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;74:1105–15.[Medline]
  8. Nakanishi Y, Kodama J, Yoshinouchi M, et al. The expression of vascular endothelial growth factor and transforming growth factor-ß associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 1997;16:256–62.[Medline]
  9. Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 2005;11:3733–42.[Abstract/Free Full Text]
  10. Tempfer C, Obermair A, Hefler L, et al. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998;92:360–3.[Abstract]
  11. Mohammadi M, Ollier WE, Hutchinson IV. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells. Hum Immunol 2003;64:S125.[CrossRef]
  12. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002;13:260–4.[Abstract/Free Full Text]
  13. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635–9.[Abstract/Free Full Text]
  14. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002;3:229–32.[CrossRef][Medline]
  15. Kim EJ, Jeong P, Quan C, et al. Genotypes of TNF-{alpha}, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005;65:70–5.[CrossRef][Medline]
  16. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004;46:293–8.[CrossRef][Medline]
  17. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002;62:3369–72.[Abstract/Free Full Text]
  18. Lu H, Shu XO, Cui Y, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005;65:5015–9.[Abstract/Free Full Text]
  19. Jin Q, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005;11:3647–53.[Abstract/Free Full Text]
  20. Chomczynski P, Mackey K, Drews R, Wilfinger W. DNAzol: a reagent for the rapid isolation of genomic DNA. BioTechniques 1997;22:550–3.[Medline]
  21. Speiser P, Gharehbaghi-Schnell E, Eder S, et al. A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer 1996;74:269–73.[Medline]
  22. Hefler LA, Grimm C, Ackermann S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003;63:3066–8.[Abstract/Free Full Text]
  23. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001;7:2984–97.[Abstract/Free Full Text]
  24. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96:902–5.[CrossRef][Medline]
  25. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006;102:134–9.[CrossRef][Medline]
  26. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107:83–9.[CrossRef][Medline]
  27. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006;102:140–4.[CrossRef][Medline]
  28. Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006;102:5–7.[CrossRef][Medline]
  29. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144–51.[Abstract/Free Full Text]
  30. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–24.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 JCOHome page
M. Patel, S. Ailawadhi, F. Hernandez-Ilizaliturri, and G. E. Wilding
Vascular Endothelial Growth Factor Polymorphisms in Early-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2008; 26(19): 3289 - 3290.
[Full Text] [PDF]

Home page
 JCOHome page
R. S. Heist, R. Zhai, G. Liu, W. Zhou, X. Lin, L. Su, K. Asomaning, T. J. Lynch, J. C. Wain, and D. C. Christiani
VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 856 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Song, E. Hogdall, S. J. Ramus, R. A. DiCioccio, C. Hogdall, L. Quaye, V. McGuire, A. S. Whittemore, M. Shah, D. Greenberg, et al.
Effects of Common Germ-Line Genetic Variation in Cell Cycle Genes on Ovarian Cancer Survival
Clin. Cancer Res., February 15, 2008; 14(4): 1090 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Kim, Y. S. Chae, S. K. Sohn, Y. Y. Cho, J. H. Moon, J. Y. Park, S. W. Jeon, I. T. Lee, G. S. Choi, and S.-H. Jun
Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 62 - 66.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hefler, L. A.
Right arrow Articles by Zeillinger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hefler, L. A.
Right arrow Articles by Zeillinger, R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online